Novel uncharged local anesthetics by Hussain, Rob
ABSTRACT 
  
NOVEL UNCHARGED LOCAL ANESTHETICS 
 
Rob Hussain, Ph.D. 
Department of Biological Sciences 
Northern Illinois University, 2014 
Richard Hahin, Director 
  
  
Bupivacaine is among the most widely used local anesthetics (LAs) for invasive procedures and 
postoperative pain relief because of its long duration of action and potency. Bupivacaine carries a risk for 
cardiotoxicity and the relationship between its structure and its anesthetic action is incompletely known. 
This study was designed to characterize how changes in the aromatic ring of a class of carbamoyl piperi-
dines (CPs), which structurally resemble bupivacaine, alter anesthetic action. In most of the CPs, the car-
bonyl carbon is directly bonded to the piperidine nitrogen (called the 1N position); bupivacaine, in con-
trast, features a 2N motif. The major objective was to determine how the placement and number of methyl 
group substitutions on the aromatic rings of the CPs alters potency and reversibility of anesthetic block. 
With this information, structural changes in the CPs could be suggested to design a new and safer LA.  
The blocking action of the CPs was investigated using a modified single-sucrose gap technique 
for recording action potentials from frog and rat nerve. To assay whether CPs preferentially block open 
sodium channels, CP blocking experiments were conducted on nerves pretreated with an alpha-scorpion 
toxin. The slopes of the dose-response relationships of the CPs varied, which is consistent with the hy-
pothesis that some CPs may bind to more than one site on sodium channels. The potency of CPs with 
two methyl groups is maximized when the methyl groups are separated by two positions. Potent CPs tend 
to result in smaller recoveries from block once the CPs are removed from the nerve. Phasic blocking po-
tency increases as hydrophobicity increases. The CPs did not preferentially block open Na channels, as 
some LAs do. There was no significant difference in tonic blocking potencies of the CPs when applied to 
frog or rat nerves, suggesting that their action might be similar in humans. Among the 1N CPs, the half 
maximal blocking dose is predicted as a function of pKa, molar volume, and methyl group positions. 
However, the half maximal blocking dose for the 2N CPs depends only on pKa. These CPs might present 
less risk for toxicity than bupivacaine.  
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CHAPTER 1 
INTRODUCTION 
Anesthesia, the absence of sensation, is clinically induced to reduce the sensation of pain for 
surgery. While general anesthetics are used to produce unconsciousness, skeletal muscle relaxation, and 
analgesia, local anesthetics (LAs) are used to produce anesthesia over more localized regions. Bupiva-
caine, among the most widely used LA for invasive procedures and postoperative analgesia, is known for 
its long duration of action and considerable potency. A major aim of this work was to see how the posi-
tions of methyl group substituents in the aromatic ring of a class of carbamoyl piperidines (CPs), which 





Local anesthetics, such as bupivacaine, lidocaine, and benzocaine, usually possess a tertiary 
amine portion and a substituted aromatic group (see Figure 1). These domains are connected by an am-
ide or ester group (Shandler, 1965). Local anesthetics interact with many proteins, such as calmodulin-
sensitive proteins (Volpi et al., 1981), the sodium (Na)-potassium (K) ATPase (Sholz, 2002), magnesium- 
and calcium-dependent ATPases (Roufogalis, 1973), and various ion channels (Sholz, 2002). Local anes-
thetics are thought to produce anesthesia primarily by blocking voltage-gated Na channels (Na channels) 
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Na channels are proteins that consist of an approximately 260-kDa α-subunit (see Figure 2) in 
association with β-subunits (Catterall, 2012). The α-subunit is composed of homologous domains D1 
through D4, each containing membrane-spanning segments S1 through S6 (Catterall, 2012) (see Figure 
2). The domains of the α-subunit are arranged to form a central pore, where LAs are thought to interact 
(Hanck et al., 2009; Li et al., 1999). Na channels transition between closed, open, and inactivated states 
in a voltage-dependent manner. When the membrane potential of excitable cells increases to some 
threshold value, Na channels open and conduct Na
+
 into the cell, which depolarizes the membrane and 
produces the upstroke of an AP. 
When a Na channel opens, the positive residues of each S4, called the voltage sensor, move ex-
tracellularly (Marban, Yamagishi, and Tomaselli, 1998) briefly and rapidly. Shortly after the initiation of an 
AP, virtually all Na channels inactivate by transitioning into a non-conducting state. As the membrane 
voltage repolarizes during the AP downstroke, Na channels are able to convert to activatable closed 




Figure 2. Alpha subunit of a voltage-gated Na channel. Alpha subunit of a Na channel showing domains 
D1-D4, each with transmembrane segments S1-S6. A. Scorpion α-toxins bind to a site on the S3-S4 linker 
of D4. B. D4S6 has phenyl group-containing residues like F1579 and Y1766 in human NaV1.5, which are 
part of the LA-binding domain(s). 
 
 Many substances interact with Na channels. Tetrodotoxin and saxitoxin are potent toxins pro-
duced by Takifugu (Japanese pufferfish) and Gonyaulax (dinoflagellates), respectively, that bind to the 
outer vestibule of Na channels, whereas synthetic molecules like LAs, anti-arrhythmics, and anti-
convulsants bind to a presumptive LA receptor binding site (Catterall, Goldin, and Waxman, 2005). Na 
channels are important modulators of pain processing. TTX-resistant Na channels, for instance, have 
been shown to be involved in hyperalgesia following sensory neuron injury (Kerr et al., 2001). PPPA (2-
[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide) (Ilyin et al., 2006) and neosaxitoxin (Ro-
driguez-Navarro et al., 2007), both Na channel blockers, have also been shown to effect pain relief. Since 
LAs are used to attenuate pain, LA-Na channel interactions are essential to successful anesthesia. 
The substituted aromatic groups of LAs are important for producing anesthesia, as these groups 
significantly interact with Na channels (Li et al., 1999). Molecular modeling by Lipkind and Fozzard (2010) 
suggested that the aromatic groups of the LAs bupivacaine, lidocaine, mepivacaine, and etidocaine inter-
acted primarily with Y1586 of the D4S6 segment of Na channels, which is also the putative major drug-
binding site (Catterall, 2012). Kuroda et al. (1996) showed that the aromatic quinoline group of the LA 
dibucaine affects inactivation. Kuo, Huang, and Lou (2000) discovered that a number of molecules con-
taining two aromatic groups, including diphenhydramine, phenytoin, and imipramine, selectively bind inac-
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tivated channels. Strother et al. (1977) found that methyl-group substitutions on the aromatic ring of lido-
caine influenced both its potency and toxicity.  
One major aim of this work was to determine how the structure of the substituted aromatic groups 
of the CPs alters AP blocking potency and reversibility of block.  Armed with this information, changes in 
the bupivacaine structural platform could be made to design new and safer LAs.  
 
 
Developments That Led to Bupivacaine 
 
Cocaine was first isolated by Gaedcke in 1855 and was regularly employed due to its ability to be 
topically applied and produce anesthesia (Finucane, 1999). However, cocaine’s use resulted in convul-
sion, cerebral excitement, and paralysis. The ester-linked LAs, which includes procaine, were first synthe-
sized in 1905, and were based on cocaine’s structure. While procaine lacked cocaine’s euphoric and ad-
dictive qualities, it nevertheless produced symptoms like restlessness, convulsion, respiratory failure, and 
cardiac arrest (Raj, 2002). In fact, many LAs produce various excitatory and cardiovascular effects at cer-
tain doses and can be particularly toxic if inadvertently administered intravascularly. Significant excitatory 
effects of LAs include grand mal convulsion and muscular twitching (Swain, 1996), while cardiovascular 
effects included reduced cardiac contractility, increased heart rate, and cardiomyopathies (Schwartz, 
Rezkalla, and Kloner, 2012).  
The amide-linked LAs, which include lidocaine and bupivacaine, have more favorable chemical 
properties than the ester LAs. Lidocaine, synthesized in 1943, was shown to have great stability in solu-
tion, fail to produce irritation at the injection site, and was adequate for dentistry (Raj, 2002), relative to 
the ester LAs. af Ekenstam et al. (1957) first synthesized bupivacaine (see Figure 3) among other N-
alkylated pyrrolidine and piperidine carboxylic acids. Each of these acids featured a carbonyl carbon at-
tached to a pyrrolidine or piperidine group to produce an α-, β-, or γ-amide (see Figure 3). af Ekenstam et 
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al. (1957) determined fundamental chemical characteristics related to the toxicity and potency of these 
amides. For instance, the α-amides were nearly three times as toxic as the β- and γ-amides (as meas-
ured by subcutaneous injections in rats), were nearly 3.5 times as potent as β-amides (as measured by 
rat ulnar nerve block), were seven times as potent as γ-amides, had the longest duration of action, and 
had among the highest therapeutic indices
 
(af Ekenstam et al., 1957). Bupivacaine, an α-amide, was 
among the most toxic, most potent, and longest-lasting of the pyrrolidine- or piperidine carboxylic acid-
based LAs. Alkylation of the piperidine nitrogen of bupivacaine increases toxicity; among the α-amides 
with the 2,6-dimethylphenyl structure, toxicity increased as the alkyl substituent bonded to the piperidine 
nitrogen lengthened in the following order: -CH3, -C2H5,, n-C3H7,, n-C4H9 (af Ekenstam et al., 1957). The 
effect of aromatic ring substituents on toxicity depended on the substituent: replacing the 2-methyl group 
of 1-ethyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with chlorine resulted in a compound about 
1.5 times as toxic, while substitution of the 2-methyl group of 1-ethyl-N-(2-methylphenyl)piperidine-2-
carboxamide with the 4-methoxy group resulted in a compound about 1.4 times less toxic  (af Ekenstam 
et al., 1957).  
 
 
Figure 3. Structure of bupivacaine, an α-amide. Bupivacaine’s butyl group substituent on its piperidine 
nitrogen enhances its potency and toxicity. 
 
Bupivacaine is today’s de facto standard LA for infiltration, spinal, epidural, and caudal anesthe-
sia (WHO Model Prescribing Information). Nevertheless, bupivacaine is potently cardiotoxic and can pro-
duce neurotoxic effects upon inadvertent intravascular administration (Finucane, 1999); at certain plasma 
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concentrations, bupivacaine has been shown to cause cardiovascular depression, ventricular arrhythmias 
and fibrillation, respiratory arrest, and convulsion. Modification of bupivacaine’s structure has already 
been shown to reduce toxicity, among other pharmacodynamic changes. Bupivacaine’s S-(-) enantiomer, 
levobupivacaine, for instance, was found not only to be less toxic, have a longer duration of action, and 
be less potent than racemic bupivacaine (Balser et al., 1996; Morrison et al., 2000). However, ropiva-
caine, an S-(-) enantiomer with a propyl group substituent on the piperidine nitrogen, carries nearly the 
same risk for cardiac arrest as racemic bupivacaine (Morrison et al., 2000). The structure-activity relation-
ship for LAs with bupivacaine’s structural platform is not completely understood. 
Most of the CPs in this study are not α-amides like bupivacaine, as the carbonyl carbon is directly 
bonded to the piperidine nitrogen and the piperidine nitrogen lacks substitution, which af Ekenstam et al. 
(1957) found was associated with toxicity. Consequently, these CPs might present less risk for toxicity 
than bupivacaine. The CPs also represent a class of LAs that af Ekenstam et al. (1957) did not synthe-
size and which have not been evaluated previously for anesthetic action. This work determined several 
properties of the CPs that can be understood in the context of LA mechanisms of action.  
 
 
LAs Modify Na Channel Activation 
 
LAs bind to putative receptor(s) located within the pore of Na channels (Sholz, 2002). Activatable 
Na channels can rapidly and reversibly bind LA before inactivating (Butterworth and Strichartz, 1999). 
LAs also bind closed and inactivated channel states and promote a longer-lasting inactivated state and 
can bind intermediately activated states to interrupt channel activation (Butterworth and Strichartz, 1999; 
Muroi and Chanda, 2009; Sheets and Hanck, 2003; Sheets and Hanck, 2007), suggesting that LAs inter-
fere with activation rather than directly occlude the channel pore. Later components of gating currents are 
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blocked more than earlier ones in the presence of LAs, leaving earlier activation processes relatively in-
tact (Butterworth and Strichartz, 1999). Some LAs are particularly beneficial because they alter certain Na 
channel states preferentially. While LAs block Na channels, some do so with greater potency when Na 
channels open more frequently, a phenomenon called use-dependent or phasic block (Strichartz, 1976; 
Sholz, 2002; Scheuer, 1999).  
 
 
Phasic Block by LAs 
 
Tonic block describes channel block at membrane potentials that do not activate Na channels 
and cause channels to occupy closed states with greater probability. Tonic block is associated with a de-
crease in Na current and a hyperpolarizing shift in the voltage dependence of inactivation, but phasic 
block is associated with higher-affinity LA-channel binding to open and inactivated channel states (Sholz, 
2002). Drugs, such as anticonvulsants and antiarrhythmics, that phasically block Na channels act to sup-
press high-frequency APs associated with epilepsies and arrhythmias, respectively (Carocci et al., 2010). 
Pain syndromes, such as erythromelalgia and paroxysmal extreme pain syndrome (Dabby, 2012), are 
associated with ectopic high-frequency Na channel openings that produce a phenomenon called phasic 
pain. There are certain advantages to having drugs that are potent phasic channel blockers. For anticon-
vulsants and antiarrhythmics, phasic block must be sufficient to block Na channels in abnormally depolar-
ized tissue to a greater extent compared to channels in normally polarized tissue. 
Phasic block results from the accumulation of LA binding to Na channels as channels open re-
peatedly in response to successive stimuli, causing increased block. Increasing depolarization duration, 
which increases the probability that Na channels are open or inactivated, increases the degree of channel 
binding for some LAs (Li et al., 1999). During high-frequency depolarization, there are relatively reduced 
periods of hyperpolarization; as hyperpolarization causes channel closing and LAs consequently to disso-
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ciate from channels, reducing hyperpolarization durations produce less LA dissociation and net accumu-
lation of block.  
Phasic block is associated with modification of gating currents that result from LA-mediated stabi-
lization of D3S4 and D4S4 in the activated position (Hanck et al., 2009). Several studies suggest that the 
aromatic group of a phenylalanine residue in D4S6 (F1759 in NaV1.5) is significant for phasic blocking po-
tency and block of gating currents (Hanck et al., 2009). A tyrosine residue in D4S6 also affects phasic 
block by LAs, but does not affect tonic block (Li et al., 1999). The protonated amine portions of LAs might 
interact with residues in D4S6 in open and inactivated channels via cation-pi electron interactions in the 
same way tetraethylammonium binds potassium channels or acetylcholinesterase binds nicotinic acetyl-
choline receptors (Li et al., 1999). Compared to phasic block, tonic block by lidocaine is voltage-
independent and is associated with low-affinity channel binding. Hanck et al. (2009) characterizes this 
“lipophilic block” by the interaction of uncharged lidocaine with neutral residues in the closed state. 
Inactivation is vital for LA binding (Strichartz, 1977); the removal of fast inactivation removes high-
affinity channel block due to lidocaine and quaternary LAs (Hanck et al., 2009; Chahine et al., 1992; 
Wang et al., 1987; Bennett et al., 1995). Li et al. (1999) suggest LA binding affinity is between 10 to 100 
times higher for open and inactivated states than for closed states (Kambouris et al., 1998; Son, Wong, 
and Stricharz, 2004). There is significant LA binding to the inactivated state: the half-blocking concentra-
tion of lidocaine decreases over one magnitude when channels are inactivated compared to other chan-
nel states (Bean, Cohen, and Tsien, 1983). The aromatic moieties of lidocaine and dibucaine are thought 
to interact with the inactivation gate of Na channels via pi-pi stacking (Kuroda et al., 2000). Voltage clamp 
experiments suggest that an asparagine (N434 in Nav1.4) in D1S6 and a leucine (L1280 in Nav1.4) in D3S6 
in inactivated channels interact with bupivacaine (Nau et al., 2003); D1S6 and D3S6 are components of the 
putative LA receptor and may be related to inactivation. Additionally, LA binding is considerably affected 
by slow inactivation, a state induced by very prolonged depolarization that requires much longer recovery 
times than fast inactivation (Khodorov et al., 1976). Balser et al. (1996) found that elimination of slow in-
activation inhibits phasic block by lidocaine and that slow-inactivated channels remain blocked longer 
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than fast-inactivated channels; they proposed that recovery from slow inactivation potentiates phasic 
block.  
LA binding of the inactivated state delays a channel’s recovery from inactivation (Chernoff and 
Stricharz, 1989; Sheets, Jarecki, and Cummins, 2011; Chevrier, Vijayaragavan, and Chahine, 2004; 
Bean, Cohen, and Tsien, 1983) and its return to the closed state, prolonging channel block. Recovery 
from inactivation of LA-bound channels is slow. The rate of recovery from inactivation of LA-bound chan-
nels might be limited by the slow rate of LA dissociation (Courtney, 1981). Alternatively, recovery from 
inactivation could be limited by activation and/or inactivation gates. According to Yeh’s m-gate trapping 
hypothesis (1985), LA dissociation requires an open activation gate, which occurs primarily at hyperpolar-
izing potentials. This hypothesis may explain the relatively higher affinity of tertiary amine LAs for the in-
activated state (Yeh and Tanguy, 1985). Yeh and Tanguy (1979) further suggested that channel opening 
is the rate-limiting step in the dissociation of quaternary LAs from inactivated channels.  However, Yeh 
and Tanguy (1979) also submit that the rate-limiting step for lidocaine dissociation from inactived chan-
nels is deprotonation. Taken together, Yeh and Tanguy’s hypotheses suggest that the charged forms of 
tertiary amine LAs dissociate only when channels are open, and inactivation interferes with LA dissocia-
tion. However, LAs in their uncharged forms may be able to leave the closed or inactivated channel rapid-
ly through the lipid bilayer. Chernoff and Stricharz (1989) stated that LAs must be charged to demonstrate 
phasic blocking capability. The dissociation of uncharged LAs may be as rapid as the rate of recovery 
from channel inactivation, which would make phasic blocking undetectable (Chernoff and Strichartz, 
1989). 
Two major hypotheses attempt to explain the molecular mechanism of phasic block. The guarded 
receptor hypothesis states that LA access to receptor(s) on Na channels, but not LA affinity, depends on 
channel state (Chernoff and Strichartz, 1989; Starmer, Grant, and Strauss, 1984). Hille’s modulated re-
ceptor hypothesis (1977), however, claims that LA receptor binding affinity, but not access, depends on 
channel state. This hypothesis is based on the fact that tonic and phasic blocking potencies of QX-314 
are enhanced while Na channels are open (Chernoff and Strichartz, 1989). Both hypotheses assume that, 
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once a LA binds, the Na channel becomes non-conducting until the LA dissociates. The potency of LAs in 
blocking Na channels depends on a number of physico-chemical properties.  
 
 
Bupivacaine Displays Cardiotoxicity in Humans 
 
 It has been suggested that ropivacaine, (S)-1-propyl-N-(2,6-dimethylphenyl)piperidine-2-
carboxamide, is less cardiotoxic than bupivacaine, (RS)-1-butyl-N-(2,6-dimethylphenyl) piperidine-2-
carboxamide (Bader et al., 1989). Bupivacaine, but not ropivacaine, includes an n-alkyl substitution on the 
piperidine ring, which was previously found to enhance its potency and toxicity (af Ekenstam et al., 1957). 
All other test agents in the current study lack n-alkyl substituents, which may make them less cardiotoxic 
than bupivacaine. Because potency and toxicity correlate fairly well for bupivacaine and its analogs (af 
Ekenstam et al., 1957), cardiotoxicity may be predicted from potency; bupivacaine is more potent than 
ropivacaine (Bader et al., 1989; Bariskaner et al., 2007).  
 The presence of n-alkyl substituents on the piperidine nitrogen of lidocaine and its analogs also 
correlate with potency. Bokesch, Post, and Strichartz (1986) showed that the CAP blocking potency of 
lidocaine homologs with alkyl group substitutions on the tertiary amine nitrogen, increased with the chain 
length of the substituents, decreased with the length between the nitrogen atoms, and increased with par-
tition coefficient.  
 Bupivacaine binds to inactivated Na channels and slowly dissociates from the channels during 
hyperpolarization, despite the fact bupivacaine preferentially binds open channels (Courtney, Kendig, and 
Cohen, 1978); these effects likely increase bupivacaine’s cardiotoxicity. Cardiac Na channels spend a 
relatively large fraction of time in the inactivated state and may display structural motifs that cause LAs to 
block them more than skeletal muscle Na channels. Nuss, Tomaselli, and Marbán (1995) found that the 
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cardiac Na channels exhibited larger tonic and phasic blocks by lidocaine than skeletal muscle channels. 
Bupivacaine blocked Na currents better than lidocaine (Clarkson and Hondeghem, 1985) and showed 
phasic blocking action consistent with an affinity for inactivated states.  
  Karoly et al. (2010) suggested that the Na channel blocking potency of an agent depends on its 
preference for binding inactivated states. Anticonvulsant drugs like lacosamide (Errington et al., 2008) 
and phenytoin (Lenkowski et al., 2007) act to block Na channels and preferentially bind inactivated chan-
nel states. In summary, bupivacaine has an n-alkyl substitution on its piperidine ring that appears to 
cause it to bind to the inactivated state of the Na channel in such a way that it enhances its cardiotoxicity. 
 
 
Physico-Chemical Properties of LAs 
 
Molecular charge is an important determinant of LA potency (Chernoff and Stricharz, 1990; Muroi 
and Chanda, 2009). The charged lidocaine derivatives QX-314 and QX-222 have higher potencies when 
applied intracellularly versus extracellularly, which suggests that LAs must penetrate the lipid bilayer to 
access LA receptors (Chernoff and Stricharz, 1990; Stricharz, 1977; Sholz, 2002). Hydrophilic quaternary 
LAs phasically inhibit Na channels by accessing receptors in open channel states intracellularly via what 
is called the hydrophilic pathway (Strichartz, 1977). Tertiary amine and quaternary LAs bind significantly 
during repetitive depolarization, during which there is more access to LA receptor(s) via the hydrophilic 
pathway (Hille, 1977). The uncharged forms of tertiary amine LAs and more lipid-soluble LAs, however, 
may directly access LA receptor(s) through the lipid bilayer via the hydrophobic pathway (Hille, 1977). 
Because they can rapidly dissociate and escape via the hydrophobic pathway, uncharged LAs likely pro-
duce considerably smaller degrees, or undetectable degrees, of phasic block than their charged conge-
ners. The onset of and recovery from block by tertiary amine LAs is more rapid at alkaline extracellular pH 
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(Hille, 1977; Lee, Sunami, and Fozzard, 2001). Alkaline extracellular pH further facilitates LA membrane 
diffusion (Hille, 1977) and increases LA binding to activated channels (Chernoff and Stricharz, 1990). 
The onset rate of channel block and potency are determined to some degree by LA hydrophobi-
city and size (Muroi and Chanda, 2009; Shandler, 1965). Langerman, Bansinath, and Grant (1994) 
showed that the concentration of a number of LAs, including bupivacaine and lidocaine, to block half the 
height of APs correlated with partition coefficients. For a number of 2,6-dimethylcarboxamide derivatives 
with similar pKa’s, including bupivacaine, lidocaine, and glycylxylidide, tonic blocking potency increased 
with the partition coefficient of the uncharged species (Chernoff and Strichartz, 1990). Hydrophobic LAs 
are generally more potent tonic blockers and have larger onset rates (Chernoff and Strichartz, 1990). LAs 
with alkyl group substitutions on the amino nitrogen and aromatic ring, as bupivacaine has, tend to have 
greater hydrophobicities and may lead one to predict bupivacaine to have a large onset rate. Neverthe-
less, considerably large hydrophobicities, as seen with bupivacaine, produce slower onset rates than ex-
pected (Norton, 2008). Bupivacaine’s relatively large size and hydrophobicity most likely slows its diffu-
sion through lipid bilayers and its partitioning into adventitia, perineuria, etc., before reaching Na channel 
receptor(s). Large partition coefficients, which correlate with relatively large hydrophobicities, prolong du-
ration of action, as is the case with bupivacaine (Muroi and Chanda, 2009). LA potency most likely can be 
better predicted from a combination of determinants like pKa and partition coefficient, as LAs with compa-
rable partition coefficients can show potency increases or decreases with pKa (Chernoff and Strichartz, 
1990). 
 Substitutions on the aromatic ring also influence LA potency. Haeseler et al. (2002) showed that 
2,6-dimethylphenol, which shares the substituted aromatic ring moieties of bupivacaine and lidocaine, 
blocked Na channels better than lidocaine and the degree of block increased as membrane potential in-
creased; these results show that 2,6-dimethylphenol blocks channels in a similar way as lidocaine does 
without having lidocaine’s tertiary amine portion. The type and location of substitutions on the aromatic 
ring of a LA may alter its blocking potency. 
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Na channels that are modified in their gating kinetics typically produce APs that are altered in size 
and shape. Such modification, particularly the delaying of channel inactivation, has been previously 
shown to produce paramyotonia and hyperkalemic periodic paralysis (Cannon, 1996; Cannon and Corey, 
1993). The interaction between LAs and molecules called activators, which affect channel inactivation, 
has yielded insight into the nature and location of the LA receptor(s). The following section provides an 





Activators like batrachotoxin (BTX) and vertatridine allow Na channels to open at potentials at 
which channels ordinarily would be non-conducting and significantly reduce the probability of inactivation, 
which causes channels to produce additional currents. Some activators reduce single-channel conduct-
ance and bind channels with greater affinity as depolarization frequency increases. While some activators 
selectively bind inactivated Na channel states (Willow and Catterall, 1982), activators such as BTX and 
veratridine bind open states to induce a persistent Na current. Veratridine, for example, binds open states 
and consequently depolarizes the membrane in a manner similarly observed in the rise of an AP (Wang 
et al., 2006). Veratridine appears to bind at a site inside the Na channel pore near LA receptor(s) (Son, 
Wong, and Strichartz, 2004; Wang et al., 2006) that involves all S6 segments. Scorpion α-toxin activators 
typically inhibit inactivation so that Na currents are prolonged but do not alter the voltage dependence of 
their opening and closing. 
Scorpion α-toxins, such as those from Buthus martensii Karsch (BmK), interact with Na channels 
(Possani et al., 1999; Tan et al., 2001). Scorpion α-toxins are approximately 60-70 residue-long peptides 
that possess a conserved core typically consisting of an α-helix and three antiparallel beta strands. Scor-
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pion α-toxins inhibit fast inactivation, resulting in channels that can activate at lower membrane potentials, 
repetitively open, and produce APs with prolonged downstrokes (Possani et al., 1999). These toxins have 
been shown to prevent the outward movement of D4S4 during activation (Campos et al., 2008; Catterall et 
al., 2007). Two α-toxins from the scorpions Leiurus quinquestriatus, LqIIa, and Centruroides sculpturatus, 
CsIVa, were shown to dissociate from channels and restore inactivation after a set of repetitive depolari-
zations was applied to the channels (Stricharz and Wang, 1986). These results suggest that toxin binding 
is voltage dependent. In addition, LAs tend to block scorpion α-toxin-bound Na channels preferentially. 
For instance, Khodorova et al. (2001) found that lidocaine rapidly blocked repetitively firing compound 
APs produced by channels activated by toxins from anemone or scorpion. 
 LAs competitively and allosterically inhibit some activators (Wang et al., 2006; Willow and Catter-
all, 1982; Willow et al., 1986). Higher concentrations of veratridine are required to depolarize membranes 
pretreated with lidocaine, which may imply competitive inhibition between LAs and activators similar to 
veratridine (Wang et al., 2006). The potency of LAs to block BTX-treated Na channels is reduced, sug-
gesting LAs dissociate BTX from Na channels initially activated by BTX (French, Zamponi, and Sierralta, 
1998; Willow et al., 1986; Wang and Wang, 1992). LAs have previously been used therapeutically for 
myotonia and pain syndromes (Chabal, Russell, and Burchiel, 1989), conditions that involve the delaying 
and/or elimination of Na channel inactivation and that are mimicked by the action of some activators. 
 
 
Objectives and Major Conclusions 
 
Bupivacaine’s action, particularly its toxicity, is due to its chemical structure. Local anesthetics, 
especially bupivacaine, possess the risk for malignant arrhythmia, hypotension, conduction delay, and 
cardiovascular collapse (Morrison et al., 2000). Although ropivacaine and levobupivacaine, more recent 
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bupivacaine congeners, have been shown to have lower risks of serious cardiotoxicity than bupivacaine, 
they are not as potent or as long-lasting as bupivacaine (Morrison et al., 2000). The CPs represent a 
class of LAs that have not been previously studied since the 1957 synthesis of bupivacaine-like LAs. It 
remains to be shown how bupivacaine’s chemical structure determines its anesthetic action. The CPs 
studied vary mainly in their substituted aromatic rings, which play significant roles in interactions with Na 
channels; therefore, differences in their action provide clues to how changes in the ring structure alters 
Na channel block. This knowledge would yield much needed insight into the development of better LAs 
and other drugs that act on Na channels. Some CPs are uncharged at physiologic pH, which will likely 
make them effective in causing AP block in inflamed regions of the body. The CPs do not have a n-alkyl 
substituent on the piperidine ring, which was previously reported to increase the cardiotoxicity of bupiva-
caine (af Ekenstam et al., 1957). 
To test the claim that changes in the number and position of substituents on the aromatic ring of 
the CPs alter anesthetic potency and properties, a number of CPs were evaluated for their tonic block, 
phasic block, and α-scorpion toxin-modified block of APs. Both CPs in which the carbonyl carbon is di-
rectly bonded to the piperidine nitrogen (the 1Ns) and to the carbon adjacent to the nitrogen on the piper-
idine ring (the 2Ns) were investigated. To determine if potency trends obtained from frog experiments ap-
ply to mammalian nerve, select CPs were evaluated for tonic block of APs in rat nerve. 
There were several important findings in this study. Bupivacaine’s structural platform, which in-
cludes the α-amide linkage, piperidine ring, and 2,6-dimethyl arrangement, is significant for AP block. 
While bupivacaine was the most potent blocker, the other CPs blocked APs in a similar manner, suggest-
ing that the CPs have clinical potential. The CPs with two methyl substituents, or the 1NXXCPs, were 
generally less potent than the CPs with one methyl substituent, the 1NXCPs. The CPs that featured bupi-
vacaine’s α-amide linkage, the 2Ns, were the most potent group of all CPs. Blocking potency depended 
on the number and position of methyl substituents on the aromatic ring. Potency was maximized when 
the methyl groups were separated by two positions. The dose-response curves for the tonic block by the 
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CPs represented a range of slopes.and may suggest CPs interact with Na channels at more than one 
site.  
This work investigated the relative reversibility, affinity for the open Na channel state, phasic 
blocking capacity, and potency in rat nerve of the CPs. Based on the degree of recovery from AP block of 
the CPs, the CPs may present fewer adverse effects than bupivacaine. Bupivacaine and the other 2N- 
CPs as a group had the lowest recoveries, which suggests that the α-amide structure is related to bupiva-
caine’s toxicity, as af Ekenstam et al. (1957) previously determined. Lidocaine, 1N34CP, and 1N35CP 
showed. an increased affinity for open channel states than for closed states but bupivacaine and all other 
CPs did not. Virtually all CPs demonstrated phasic blocking capacity. This suggests that molecular 
charge is not essential for phasic block. All CPs evaluated in rat nerve had the same tonic blocking po-






Compound APs (CAPs) were recorded from desheathed frog (Rana pipiens) sciatic nerve using 
the single sucrose gap technique (Hahin and Kondratiev, 2001) (see Figure 4). Adult grass frogs (Charles 
D. Sullivan Co. Inc., Nashville, Tennessee) were euthanized by rapid decapitation, in accordance with 
procedures approved by the Institutional Animal Care and Use Committee (IACUC). Sciatic nerves were 
dissected from the lumbar plexus to the tibial and peroneal branches just distal to the knee. If not imme-
diately used, nerves were stored in Ringer’s solution at 4°C for no longer than 3 days. The nerves were 
desheathed and mounted in the chamber with the proximal end in the intracellular pool, containing buff-
ered isosmotic KCl. The body of the nerve passed through the gap partition, which was continually per-
fused with isosmotic sucrose at a rate of 6 mL/min. The distal end of the nerve was in the extracellular 
pool and contained Ringer’s solution with or without test substances and was electrically grounded. The 
intracellular and extacellular pools were electrically isolated via petrolatum seals around the nerve and 
sucrose flow to create a resistance greater than 1 MΩ. Both KCl and Ringer’s solution were replaced eve-
ry 30 minutes to maintain solution levels in the compartments. The extracellular end of the nerve was 
placed in to an external cylindrical glass suction electrode via an applied vacuum.  The suction electrode 
contained a Ag-AgCl electrode, Ringer’s solution and paraffin oil and was electrically connected to the 
recording apparatus via shielded cable. CAPs were differentially recorded in the intracellular pool relative 
to the extracellular pool using a digitial oscilloscope (Tektronix TDS 340A, Beaverton, OR). CAPs were 
filtered using a 40 kHz filter and stored on diskettes for later analysis. Experiments were conducted at 
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room temperature only with nerves that initially had a stable CAP of at least 50 mV over a 30-min period 
and if the CAP shape did not vary with the sucrose flow rate. 
 
Figure 4. Sucrose-gap technique setup.   is the potential in the KCl chamber, relative to the extracellular 





Ringer’s solution (frog nerve) contained 112 mM NaCl, 2 mM CaCl2, 2 mM KCl, and 10 mM 4-(2-
hydroxyethyl)-1-piperazineethane-sulfonic acid (HEPES) and was adjusted to pH 7.40 using 10 N NaOH. 
Krebs solution (rat nerve) contained 135 mM NaCl, 1.8 mM CaCl2, 5.4 mM KCl, and 2.4 mM NaHCO3 and 
𝑉 








was adjusted to pH 7.40 using 2 N NaOH. Extracellular solutions were used for storing nerves, in the ex-
tracellular pool, and for producing dilutions of test agents. The intracellular solution contained 112 mM 
KCl and 20 mM HEPES, adjusted to pH 7.40 with 10 N KOH. This isotonic KCl solution counteracts the 
hyperpolarization produced by the sucrose flow and the junction potential between extracellular solution 
and sucrose (Blaustein and Goldman, 1966). The 0.18 M sucrose solution minimized extracellular shunt-
ing during CAP propagation. 
 
 
Stimulation and Recording 
 
Square wave 0.15 ms-long pulses were applied to the nerve by a Grass S48 stimulator at various 
frequencies, depending on the type of experiment. CAPs were collected at a sampling frequency of 100 
MS/sec using a data acquisition system (Measurement Computing USB-1208FS, Norton, MA) and sub-
sequently analyzed using Microsoft Excel. Baseline CAP height and duration were recorded after the 
CAP height stabilized before adding test agents to the extracellular pool.  
In tonic block experiments, recordings were taken every five minutes and six consecutive steady 
CAPs were obtained prior to test solute addition to represent baseline height. Stimuli were applied at 0.5 
pulses per second (pps). In experiments where nerves were treated with α-toxin prior to test solute addi-
tion, recordings were taken every five minutes and four consecutive control CAPs were obtained prior to 
α-toxin addition. Stimuli were applied at 0.2 pps. α-toxin was removed when CAP duration was at least 50 
ms, and test solute was immediately added in Ringer’s solution after α-toxin was removed. In phasic 
block experiments, a 1-second train of pulses at either 10 pps or 20 pps was applied and the degree of 
attenuation of CAP block between the first and last pulses was used to evaluate phasic block capability 





The original set of CPs, shown in Table 1, were purchased from Sigma Chemicals (St. Louis, 
Missouri); bupivacaine and lidocaine were purchased from Abbott Laboratories. CP solutions were pre-
pared using a volume per volume dilution in extracellular Ringer’s or Krebs solution and were adjusted to 
pH 7.40. ChemSketch was used to estimate the octanol-water partition coefficient and SPARC (Sparc 
Performs Automated Reasoning in Chemistry) was used to estimate pKa.  
 
Table 1 













identifier  substituents* 
1N2CP 1-(N-(o-tolyl)carbamoyl)piperidine R1 = CH3 
1N3CP 1-(N-(m-tolyl)carbamoyl)piperidine R2 = CH3 
1N4CP 1-(N-(p-tolyl)carbamoyl)piperidine R3 = CH3 
1N25CP 1-(N-(2,5-xylyl)carbamoyl)piperidine R1 = CH3,  R4 = CH3 
1N34CP 1-(N-(3,4-xylyl)carbamoyl)piperidine R2 = CH3,  R3 = CH3 
1N35CP 1-(N-(3,5-xylyl)carbamoyl)piperidine R2 = CH3,  R4 = CH3 
1N26CP 1-(N-(2,6-xylyl)carbamoyl)piperidine R1 = CH3,  R5 = CH3 





Buthus martensii Karsch (BmK) 16(5) α-toxin, previously isolated and purified by Hahin, Chen 
and Reddy (2000), was used to lengthen the duration of CAPs by direct application to Ringer’s solution 
bathing the nerve and be referred to as α-toxin Ringer’s solution.  
 
 
Potency and Recovery Calculations 
 
CAP recordings were obtained using the following procedure. CAPs were recorded in Ringer’s (or 
in α-toxin Ringer’s) control solution followed by a test solution containing a CP in Ringer’s solution and 
finally in Ringer’s solution. To remove the test solute solution, three washouts with Ringer’s solution was 
used. CAP recordings were used to obtain the time course and degree of AP block in the test solution. 
The relative CAP height or duration defined by steady state height or duration values due to test solute, 
referred to as response, was measured. After the test solute solution was replaced with Ringer’s solution, 
elicited CAPs grew in height until the heights achieved some steady state value, defined to be the CAP 
height that remains unchanged for 30 minutes. Reversibility of block, referred to as recovery, was esti-
mated by the steady-state CAP height in Ringer’s solution (after the test solute was removed) divided by 
the corresponding CAP height in Ringer’s solution prior to the addition of test solute. Dose-response and 
dose-recovery relations were fit by the logistic equations (1)-(4). The dose-response curve for CAP height 
block has the form 
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where   ( ) is CAP height relative to baseline height at concentration   (in mM),       is half-height 
blocking concentration (in mM), and    is the slope parameter. The dose-response curve for CAP dura-
tion block has the form 
 
where   ( ) is CAP duration relative to baseline duration at concentration   (in mM),       is the half-
duration blocking concentration (in mM), and    is the slope parameter. The dose-recovery curve for CAP 
height block has the form 
 
where   ( ) is CAP height recovery relative to baseline height at concentration   (in mM),        is the 
concentration (in mM) at which relative recovery is    , and    is the slope parameter. Finally, the dose-
recovery curve for CAP duration block has the form 
 
where   ( ) is CAP duration recovery relative to baseline duration at concentration   (in mM),        is 
the concentration (in mM) at which relative recovery is    , and    is the slope parameter. The Leven-
berg–Marquardt algorithm was used to obtain least-squares estimates of the parameters      ,      , 
      ,       ,   ,   ,   , and    for each CP. Blocking potency was defined as the reciprocal of ED50. 
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Figure 5 shows the general reaction scheme for the synthesized CPs. Table 2 shows the final 
synthetic products. 1-BOC-piperidine-2-carboxylic acid (1, 1 mmol, 1 eq), the appropriate substituted ani-
line (2, 1 mmol, 1 eq), and HOBt (3, hydroxybenzotriazole, 1 mmol, 1 eq) in anhydrous CH2Cl2 (50 
mL) was stirred at 0°C under inert atmosphere (N2). A solution of EDC HCl salt (4, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride, 1 mmol, 1 eq) with Et3N (5,1 mmol, 1 eq) in anhydrous 
CH2Cl2 (10 mL) was added dropwise under inert atmosphere at reduced temperature. The resulting solu-
tion was allowed to warm to room temperature following complete addition of the EDC solution. After 24 
h, the solution was poured over EtOAc (100 mL) and the organic layer was washed with water (2 x 50 
mL), washed with brine (2 x 50 mL), and dried over anhydrous sodium sulfate. The reaction solvent was 
removed in vacuo, yielding crude product as a yellow solid. HCl was used to deprotect the product. Purifi-
cation was carried out via flash chromatography on silica gel utilizing a hexane:EtOAc gradient (0% 
EtOAc to 50% EtOAc). Fractions were analyzed by TLC (30% EtOAc:hexane) and product fractions were 
collected and concentrated, yielding 6a-c (see Table 2) as a white solid. Reaction progress was moni-
tored using analytical thin-layer chromatography on pre-coated silica gel plates and the spots were de-
tected under 254 nm. All reagents and solvents were purchased from Sigma-Aldrich and used without 
further purification.  
 
Figure 5. General scheme of syntheses. Reactions were performed under anhydrous conditions. 
 
0°C, 2 h 






*unmentioned R groups are hydrogen atoms 
 
1
H NMR were recorded in deuterated chloroform at 300MHz on a Bruker NMR spectrometer. 
Chemical shifts are expressed in ppm.  
2NCP:  
1
H NMR (500 MHz, CDCl3, ppm): 1.46-1.64 (4H, m, CH2), 1.75 (1H, s, NH), 1.83-1.85 (1H, m, 
CH2), 2.05 (1H, dd, CH2), 2.78 (1H, dt, CH2), 3.08 (1H, dt, CH2), 3.36 (1H, dd, CH), 7.11 (1H, 
t, Ar), 7.34 (2H, t, Ar), 7.59 (2H, d, Ar), 8.87 (1H, s, NH) 
2N24CP:  
1
H NMR (500 MHz, CDCl3, ppm): 1.50 (2H, d, CH2), 1.63 (3H, s, CH2), 1.84 (1H, s, NH), 2.07 
(1H, s, CH2), 2.26 (3H, s, CH3), 2.30 (4H, s, CH3), 2.81 (1H, s, CH2), 3.11-3.13 (1H, m, CH2), 
3.48 (1H, dd, CH) , 7.01 (2H, s, Ar), 7.78 (1H, d, Ar), 8.84 (1H, s, NH) 
2N246CP:  
1
H NMR (500 MHz, CDCl3, ppm): 1.25 (1H, s, NH), 1.50-1.60 (2H, m, CH2), 1.70 (2H, t, CH2), 
1.71-1.87 (2H, m, CH2), 2.12 (2H, dd, CH2), 2.20 (6H, s, CH3), 2.28 (3H, s, CH3), 2.83-2.88 
(1H, m, CH), 3.17 (1H, d, CH), 3.56 (1H, t, CH), 6.90 (2H, s, Ar), 8.31 (1H, s, NH) 
 
Identifier  CH3 substituents*  
6a. 2NCP N-(phenyl)piperidine-2-carboxamide none 
6b. 2N24CP N-(2,4-dimethylphenyl)piperidine-2-carboxamide R1, R3 
6c. 2N246CP N-(2,4,6-trimethylphenyl)piperidine-2-carboxamide R1, R3, R5 
CHAPTER 3 
RESULTS 
CP Tonic Block 
 
CPs blocked CAP heights in a concentration-dependent manner. Figures 6-11 show the typical 
protocol used to obtain dose-response data for tonic block experiments for each test agent. The dose 
used, percent block (blk), and percent recovery (rec) are given for three doses for the shown to the right 
of each panel (A, B or C). After the CAP height stabilized for a 30-minute period, the Ringer’s solution 
was replaced (indicated by C in each figure) by a test agent in Ringer’s solution. The time course of CAP 
block was obtained by eliciting CAPs until a steady-state block occurred. After steady-state block was 
observed, the test agent solution was replaced by Ringer’s solution (indicated by R in each figure). CAPs 
were elicited every 2 sec throughout the experiment. If recovery was at least 90% of the control CAP 
height and the post-test solute CAP remained unchanged in height for 30 minutes, a second dose of the 
same test agent was applied to the same nerve to reduce the variation caused by using different nerves. 
In experiments where more than one dose of the same test agent was applied to the same nerve, the or-
der of the doses evaluated was randomized. As concentration increased, CAP block increased. CAPs 
































blk  17.8%  




blk  64.9%  




blk  74.1%  



































blk  10.5%  




blk  27.9%  




blk  53.2%  



































blk  7.9% 




blk  11.9% 




blk  29.7% 


































blk  10.0% 




blk  52.5% 




blk  69.0% 


































blk  14.9% 




blk  53.1% 




blk  68.3% 


































blk  48.7% 




blk  77.6% 




blk  85.4% 









Tonic Block Relations 
  
Figures 12-14 show the tonic block dose-response relations for all CPs. To produce dose-
response relations, results for five different doses with at least three replicates per dose were obtained for 
each solute. Each figure contains standard error bars. Figure 12 and 13, respectively, show dose-
response relations for CPs that feature the 1N- structure and have two methyl group substituents on the 
aromatic ring (1NXXCPs) or one methyl group substituent (1NXCPs). Figure 14 shows dose-response 
relations for the 2N- CPs. Dose-response relations for all test agents, except for bupivacaine and lido-
caine, are represented by unfilled symbols.  
All curve fits had   < 0.01. Figures 12-14 show that the dose-response curves for the test agents 
exhibit a wide range of slopes and generally cannot coincide with other curves simply through horizontal 
shifts. However, the curves for bupivacaine and 2N246CP ( ) are very similar in shape. 
 
Figure 12. Dose-response curves for bupivacaine and 1NXXCPs. Bupivacaine (♦), lidocaine (■), 1N25CP 





Figure 13. Dose-response curves for bupivacaine and 1NXCPs. Bupivacaine (♦), lidocaine (■), 1N2CP 




Figure 14. Dose-response curves for bupivacaine and 2N- CPs. Bupivacaine (♦), lidocaine (■), 2NCP (□), 
2N24CP (○), and 2N246CP ( ).  
 
Figures 15 and 16 represent tonic block dose-recovery curves for the 1NXXCPs and 1NXCPs, 
respectively. Each figure contains standard error bars. Dose-recovery curves for bupivacaine and lido-
caine are displayed in each figure for comparison purposes. All curve fits had   < 0.01, except for 1N3CP 
(  = 0.0162) and 1N4CP (  = 0.0146). The recovery relationships illustrate that recovery was dose-
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dependent. The shapes of the recovery relations varied considerably, showing that the degree of recov-
ery was dependent on CP structure. 
 
Figure 15. Dose-recovery curves for bupivacaine and 1NXXCPs. Tonic block dose-recovery curves for 
bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○), 1N35CP ( ), and 1N26CP ( ).  
 
 
Figure 16. Dose-recovery curves for bupivacaine and 1NXCPs. Tonic block dose-recovery curves for bu-
pivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 1N4CP ( ).  
 
Table 3 shows tonic block dose-response and dose-recovery curve parameters and chemical 
properties for all test agents. Bupivacaine, lidocaine, and the other CPs tested are shown in the first col-









































the acid dissociation constant (expressed as –          ), and the block and recovery parameters (i.e., 
     ,   ,       , and   ) obtained from curve fits to dose-response and dose-recovery relations. Using 
the dose-recovery relationships, an estimate for the expected amount of recovery,     , at the       
dose was obtained and is shown as the last column entry in the table:        (     ).  
Table  3 
Test Agent Chemical Properties and Tonic Block Parameters. 
vol = molar volume in mL; log P = log octanol-water partition coefficient;       in mM;    = slope parame-
ter;        in mM;    is the test agent potency relative to bupivacaine;      is the estimated relative re-
covery at the ED50 concentration (       (     )). ± indicates standard error. 
 chemical properties  tonic block parameters  
 
vol log P pKa                           
bupivacaine 279.48 3.64 8.07 0.83±0.05 2.43±0.30 1.22±0.09 1 0.684 
lidocaine 228.40 2.36 8.18 4.73±0.30 2.33±0.16 6.89±0.31 0.175 0.705 
1N35CP 208.73 2.83 0.39 3.34±0.07 4.20±0.39 4.20±0.30 0.249 0.744 
1N26CP 208.73 2.83 0.39 3.94±0.06 3.73±0.15 6.19±0.58 0.211 0.843 
1N25CP 208.73 2.83 0.35 7.85±0.40 1.58±0.15 10.5±0.52 0.106 0.651 
1N34CP 208.73 2.83 0.43 8.63±0.17 1.87±0.08 17.0±0.09 0.096 0.718 
1N3CP 192.30 2.37 0.19 1.70±0.01 9.41±0.69 1.98±0.06 0.488 0.748 
1N4CP 192.30 2.37 0.22 3.58±0.33 3.62±0.99 5.47±0.63 0.232 0.749 
1N2CP 192.30 2.37 0.14 8.73±0.08 4.08±0.17 12.0±0.42 0.095 0.752 
2N246CP 246.35 2.75 8.94 1.06±0.03 2.80±0.26 1.67±0.14 0.783 0.726 
2N24CP 232.32 2.29 8.73 2.38±0.18 2.92±0.75 3.21±0.15 0.349 0.662 
2NCP 204.27 1.37 8.44 4.42±0.21 4.11±0.85 5.57±0.24 0.188 0.672 




α-Toxin-Treated CAP Block 
 
To determine whether CPs block open Na channels over their closed counterparts (preferably 
block open channels), nerves were treated with a scorpion α-toxin (BmK 16(5)) that abolishes fast inacti-
vation and causes Na channels to open and close repeatedly and thus occupy the open state for a rela-
tively longer period of time. Nerves treated with BmK 16(5) exhibit CAPs that become increasingly pro-
longed the longer nerve fibers are exposed to the toxin. The CAPs develop a long “tail” and decrease 
slightly in height in the presence of the toxin. The tail develops as Na channels lose their ability to inacti-
vate when in the presence of the toxin. Bupivacaine, lidocaine, the 1NXXCPs, and the 1NXCPs were 
tested for their ability to block the heights and durations of toxin-altered CAPs. If CPs preferably block 
open channels, then the CAP tail (duration) should be blocked to a greater extent than the CAP height. 
The heights and durations of toxin-altered CAPs were reduced in a concentration-dependent manner.  
Figures 17-21 show examples of α-toxin-treated CAP block experiments for bupivacaine, lido-
caine, 1N25CP, 1N3CP, and 4mNmTPCP at three different concentrations for each test substance. Each 
of the other CPs were tested in a similar fashion, but are not shown. Each figure represents the CAP 
height (ordinate) versus time (abscissa). CAPs were stimulated frequently (see methods); however, CAPs 
are shown every 5 minutes and each CAP is shifted rightward by 5 msec to represent the progression of 
time. In each figure, the first 4 CAPs represent the baseline CAP height and duration during a 20-minute 
period prior to the addition of the BmK 16(5) toxin to the nerve. At the CAP labeled by a T, the toxin was 
applied to the extracellular solution bathing the nerve. The toxin lengthened the CAP in time; each suc-
cessively stimulated CAP exhibited a longer “tail.” After the CAP had lengthened to exactly 50 ms, the 
toxin solution was immediately replaced with Ringer’s solution containing a test agent (indicated by C). A 
set of successive CAPs was elicited until the CAP height reached a new steady-state value. After reach-
ing this steady-state height, the test agent solution was replaced with Ringer’s (indicated by an R) in order 
to wash off the test agent from the bath and observe the time course of recovery. In each figure, below 
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the concentration of the test agent are symbols that designate, in percent, the block of the height (hblk), 
the recovery of the height (hrec), the block of duration (tblk), and the recovery of the duration (trec). 
Figures 22-25 show the α-toxin-treated nerve dose-response and dose-recovery relationships for 
CAP height. Figure 22 shows α-toxin-treated nerve dose-response curves for CAP height for bupivacaine 
and the 1NXXCPs. Figure 23 shows α-toxin-treated nerve dose-response curves for CAP height for bupi-
vacaine and the 1NXCPs. In each figure, dashed traces indicate the logistic model curve fits for bupiva-
caine or lidocaine. All bars represent standard error. For all fits,   < 0.01. Figure 24 shows α-toxin-treated 
nerve dose-recovery curves for CAP height for bupivacaine and the 1NXXCPs. Figure 25 shows α-toxin-
treated nerve dose-recovery curves for CAP height for bupivacaine and the 1NXCPs. For all fits,   < 0.01, 
except for 1N3CP (  = 0.0162) and 1N4CP (  = 0.0146). 
After α-toxin treatment of nerves, CAPs were prolonged and the addition of test agents to the 
nerve shortened the duration of the CAPs. Figures 26-29 show the α-toxin-treated nerve dose-response 
and dose-recovery relationships for CAP duration. Figure 26 shows α-toxin-treated nerve dose-response 
curves for CAP duration for bupivacaine and the 1NXXCPs. Figure 27 shows α-toxin-treated nerve dose-
response curves for CAP duration for bupivacaine and the 1NXCPs. For all fits,   < 0.01. 
After removal of the test agents, the CAPs recovered to a more prolonged state, depending on 
the concentration of the test agent. After recovery reached a steady-state value, the fractional degree of 
recovery was plotted as a function of the concentration of the test agent applied to the nerve. Figure 28 
shows α-toxin-treated nerve dose-recovery curves for CAP duration for bupivacaine and the 1NXXCPs. 
Figure 29 shows α-toxin-treated nerve dose-recovery curves for CAP duration for bupivacaine and the 
1NXCPs. For all fits,   < 0.01. 
Table 4 shows α-toxin-treated nerve dose-block and dose-recovery parameters for the block of 
CAP height. Table 5 shows α-toxin-treated nerve dose-block and dose-recovery parameters for the block 






























hblk  25.4% 
hrec  79.6% 
tblk  21.2% 









































































Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C. 
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-







































































Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C. 
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-








































































Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C. 
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-







































































Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C. 
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-





























Figure 22. α-toxin-treated nerve dose-response curves for height for 1NXXCPs. α-toxin-treated nerve 
dose-response relations for CAP height for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○), 
1N35CP ( ), and 1N26CP ( ).  
 
 
Figure 23. α-toxin-treated nerve dose-response curves for height for 1NXCPs. α-toxin-treated nerve dose-
response relations for CAP height for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 1N4CP 





Figure 24. α-toxin-treated nerve dose-recovery curves for height for 1NXXCPs. α-toxin-treated nerve 
dose-response relations for CAP height for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○), 
1N35CP ( ), and 1N26CP ( ).  
 
 
Figure 25. α-toxin-treated nerve dose-recovery curves for height for 1NXCPs. α-toxin-treated nerve dose-
response relations for CAP height for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 1N4CP 











































Figure 26. α-toxin-treated nerve dose-response curves for duration for 1NXXCPs. α-toxin-treated nerve 
dose-response relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○), 
1N35CP ( ), and 1N26CP ( ). 
 
 
Figure 27. α-toxin-treated nerve dose-response curves for duration for 1NXCPs. α-toxin-treated nerve 
dose-response relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 

















































Figure 28. α-toxin-treated nerve dose-recovery curves for duration for 1NXXCPs. α-toxin-treated nerve 
dose-recovery relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○), 
1N35CP ( ), and 1N26CP ( ).  
 
 
Figure 29. α-toxin-treated nerve dose-recovery curves for duration for 1NXCPs. α-toxin-treated nerve 
dose-recovery relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 








































































Table  4 
 
α-Toxin-Treated Nerve CAP Height Block Parameters. 
 
 
      in mM;       = slope parameters;        = recovery pa-
rameter in mM. ± indicates standard error. 
 
CP                    
bupivacaine 0.75±0.05 2.70±0.40 0.98±0.03 1.73±0.12 
lidocaine 3.49±0.51 1.37±0.29 4.07±0.46 1.40±0.25 
1N35CP 3.00±0.20 3.24±0.77 3.81±0.18 5.80±01.6 
1N26CP 3.88±0.22 2.72±0.35 5.99±0.55 2.32±0.34 
1N25CP 5.90±0.19 1.40±0.47 8.32±0.63 1.81±0.27 
1N34CP 6.67±0.63 1.58±0.24 17.1±0.89 1.38±0.11 
1N3CP 1.63±0.02 11.0±1.5 1.74±0.05 5.45±01.2 
1N4CP 3.28±0.14 3.70±0.55 4.66±0.24 1.97±0.20 
1N2CP 7.69±0.04 3.64±0.09 8.87±0.72 3.21±0.87 
























Table 6 shows percent phasic block at 10 pps and 20 pps for all test agents evaluated for phasic 
block. Figure 30 show the attenuation of CAP height for 1.50 mM bupivacaine at the stimulation rates of 
10 pps (top) and 20 pps (bottom). Tonic block refers to the degree of height block of the CAP in the pres-
ence of test agent that occurs prior to stimulation. However, with repetitive stimulation, block progressive-
ly increased and the additional phasic block was obtained by comparing the last CAP height compared to 
Table 5 
 
α-Toxin-Treated Nerve CAP Duration Block Parameters. 
 
 
      in mM;       = slope parameters;        = recovery pa-
rameter in mM. ± indicates standard error. 
CP                    
bupivacaine 0.73±0.08 1.85±0.36 0.96±0.11 1.66±0.34 
lidocaine 1.53±0.15 0.93±0.09 2.42±0.51 0.89±0.20 
1N35CP 1.66±0.33 2.83±0.30 10.6±0.96 1.79±0.27 
1N26CP 3.64±0.29 1.93±0.31 5.52±0.54 1.83±0.27 
1N34CP 4.01±0.46 1.58±0.30 5.26±0.85 1.46±0.34 
1N25CP 5.43±01.0 0.87±0.18 11.0±01.5 0.75±0.08 
1N3CP 1.63±0.03 9.91±1.7 1.66±0.10 5.29±2.2 
1N4CP 3.21±0.17 2.77±0.44 4.01±0.25 2.05±0.27 
1N2CP 6.86±0.38 4.35±01.1 7.48±0.34 3.48±0.64 
4mNmTPCP 3.46±0.34 2.39±0.56 3.83±0.35 2.24±0.50 
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the pre-stimulation CAP height. Since all differences in CAP heights were less than 1 mV, these differ-
ences are difficult to discern in Figure 30. Nevertheless, the difference in heights of successive CAPs was 
approximately constant. Similar experiments were performed on all test agents besides bupivacaine and 
the 2N- CPs. The CPs were less likely to produce any additional block compared to bupivacaine and lido-
caine and this can be seen in Table 6. Table 6 shows that 1N26CP was the most effective CP in inducing 
additional block after a 20-pulse repetitive stimulation sequence. 
 
 



















Rat Tonic Block  
 
For select CPs, tonic block experiments were repeated in rat sciatic nerve in order to identify any 
significant differences in blocking action. Tonic block experiments using rat nerves were conducted (re-
sults not shown) in a manner analogous to the experiments performed previously using frog nerves. Ex-
periments were conducted using 1N34CP, 1N3CP, and 4mNmTPCP and bupivacaine as test agents. 
Figures 31 and 32 show the rat tonic block dose-block and dose-recovery curves, respectively, of the 
aforementioned test agents. All fits had   < 0.01. Rat tonic block dose-response and dose-recovery 
Table 6 
 
Phasic Block of CAP Height. 
 
 
Values are in % of block of baseline CAP 
height. ± indicate standard error. 
CP 10 pps 20 pps 
bupivacaine 1.77±0.05 2.58±0.03 
lidocaine 1.18±0.04 2.75±0.06 
1N26CP 0.98±0.11 1.20±0.08 
1N34CP 0.84±0.08 0.90±0.05 
1N25CP 0.80±0.09 1.21±0.08 
1N35CP 0.55±0.08 0.90±0.06 
1N4CP 0.54±0.06 0.69±0.06 
1N2CP 0.45±0.03 0.64±0.09 
1N3CP 0.27±0.06 0.59±0.05 
4mNmTPCP 0.60±0.03 1.15±0.06 
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curves for bupivacaine are shown for comparison purposes and indicated as a dotted trace. Table 7 com-
pares the frog tonic block and rat tonic block dose-response and dose-recovery parameters of CAP 
height of bupivacaine, 1N34CP, 1N3CP, and 4mNmTPCP. The differences in ED50s between rat and 
frog experiments per test agent were not significant.   
 
 
Figure 31.  Rat tonic block dose-response curves. Rat tonic block dose-block curves for bupivacaine (♦), 
1N34CP (□), 1N3CP (○), and 4mNmTPCP ( ).  
 
 
Figure 32.  Rat tonic block dose-recovery curves. Rat tonic block dose-recovery curves for bupivacaine 



































Rat and Frog Tonic Block Parameters for CAP Height. 
 
      in mM;       = slope parameters;        in mM. () indicate standard error. 
 
 rat tonic block parameters frog tonic block parameters 
CP                                 
bupivacaine 0.75±0.05 2.87±0.15 1.19±0.08 2.21±0.38 0.83±0.05 1.22±0.09 
1N34CP 7.85±0.40 2.27±0.86 16.9±1.3 1.53±0.21 8.63±0.17 17.0±0.09 
1N3CP 1.66±0.02 7.85±0.29 2.05±0.01 6.23±0.22 1.70±0.01 1.98±0.06 
4mNmTPCP 3.47±0.26 8.65±1.7 6.03±0.08 5.15±0.30 4.02±0.12 5.85±0.03 
CHAPTER 4 
DISCUSSION 
Comparison of Results for Lidocaine and Bupivacaine 
 
 Previous work showed that bupivacaine is a more potent tonic blocker than lidocaine. Buyukakilli 
et al. (2003) exposed frog sciatic nerve to 10 mM, 20 mM, and 30 mM bupivacaine for 20 minutes and 
recorded action potential changes.  Buyukakilli et al. (2003) obtained an estimate of the ED50 of 62.9 
mM, compared to 0.83 mM in this study.  Langerman, Bansinath, and Grant (1994) obtained ED50s for 
bupivacaine and lidocaine in mice via intrathecal spinal injections and obtained values of 0.42 mM and 
4.18.  Shown in Table 8 is a comparison of the results of the different estimates of ED50s obtained from 
AP block.  
 Buyukakilli et al. (2003) stimulated nerve tissue before and after exposure to bupivacaine and 
their estimate of ED50 was based on only 3 doses of drug. In the current study nerves were frequently 
stimulated (0.5/sec) prior to and after the application of the test agents. Buyukakilli et al. (2003) did not 
use desheathed nerves and limited the exposure time of bupivacaine to 20 minutes prior to recording the 
diminution of the CAP so diffusion limitations likely caused their results to differ from those obtained in 
this study. 
 Yano et al. (2013) characterized how lidocaine phasic block of propagated APs in crayfish giant 
axons was enhanced by dimethylsulfoxide (DMSO) in the bathing solution. In experiments without DMSO 
added (figure 3A; Yano et al. 2013), Yano et al. (2013) stimulated axons in the presence of 1 mM lido-
caine at 20 pulses per second, the stimulation rate used in this study, and found that the 20
th
 AP height 
was reduced by approximately 3.6% compared to the first AP.  All APs Yano et al. (2013) recorded were 
obtained via an intracellular microelectrode into one of the giant axons of the nerve bundle.  Results from 
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this study using the same protocol were consistent with the results of Yano et al. (2013) and showed a 
3.37% reduction in CAP height when the 20
th
 CAP was compared to the 1
st












Bupivacaine’s Structural Platform Is Significant 
 
Bupivacaine was the most potent tonic blocker; however, all other test agents had potencies with-
in one order of magnitude of bupivacaine’s. Excluding bupivacaine, 1N3CP, 2N246CP, and 2N24CP were 
the other most potent tonic blockers. There are patterns in the 1NXXCP relative potencies that suggest 
bupivacaine’s structural platform is significant for producing AP block.  
1N26CP, which shares bupivacaine’s methyl-group arrangement and piperidine ring, but lacks 
the α-amide linkage, was among the most potent CPs. 1N35CP was more potent than 1N26CP, but 
1N34CP was more than two times less potent than 1N26CP. This relative potency variation may be ex-
plained by the fact that 1N35CP and 1N26CP have similar aromatic ring methyl group placements: both 
have bupivacaine’s piperidine ring and have dimethylphenyl groups in which the methyl groups are not 
adjacent to each other. 4mNmTPCP, which has a piperidine ring and lacks methyl group substituents, 
was as potent as lidocaine. However, lidocaine has bupivacaine’s methyl substituent arrangement, but 
Table 8. 
 
AP Block ED50 Estimates for Bupivacaine and Lidocaine. 
 
 
Values in mM, ( )   standard error in, ()   standard error not giv-
en; a. current study; b. Buyukakilli et al., 2003; c. Langerman, 
Bansinath, and Grant, 1994 
 a b c 
bupivacaine 0.83 (.05) 62.9 (.70) 0.42 () 
lidocaine 4.73 (.30) -- 4.18 () 
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had one of the smallest potencies of the test agents. These observations suggest that the piperidine ring 
moiety contributes more to potency than the dimethylphenyl structure.  
However, the 2N-CPs, which featured bupivacaine’s α-amide linkage, were the most potent group 
of CPs, which suggests the α-amide linkage contributes  more to potency than either the piperidine ring or 
the dimethylphenyl structure. The addition of methyl substituents to 2NCP increased potency, with three 
methyl substituents conferring the greatest potency within this group and among all CPs after bupiva-
caine. 
 
Multiple Binding Sites for CPs 
 
Equations (1-4) describing CAP block and recovery each employ a slope parameter (  ), similar 
to the Hill slope, that describes the steepness of the curves. The Hill slope was first used by Hill to model 
the binding of oxygen (O2) to hemoglobin (Hb). Hill’s O2-Hb binding model exhibited positive binding co-
operativity; O2 binding to hemoglobin increased the probability that an additional O2 will bind the same 
hemoglobin molecule. As the degree of positive cooperativity increases, so does the Hill slope and the 
curve of the fraction of bound O2 becomes steeper, i.e., the maximum curve slope increases. The tonic 
block dose-response curves showed a range of maximum slopes   , which are akin to Hill slopes.  
When applied to dose-response relations, the Hill slope additionally provides a measure of the 
range of safely used (therapeutic) doses. Larger slopes, or steeper dose-response curves, imply a narrow 
clinical therapeutic range of doses, whereas smaller slopes, as seen in the case of 1N25CP, 1N34CP, 
and 1N2CP, suggest that these drugs would block Na channels in varying degrees over a wider range of 
doses.    can be used to quantify the approximate relative degree of cooperative binding of the test 
agents to Na channels in nerve fibers. Values of    greater than one may indicate more than one binding 
site for the test agents are present on Na channels. 
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The evidence for multiple binding sites for LAs is mixed. Dose-response relations obtained from 
lidocaine- and benzocaine-block of open Na channels (Wang et al. 2004) were both shown to exhibit Hill 
slopes of 0.9 ± 0.1, suggesting that binding is not cooperative and binding likely occurs at a single site. 
Leuwer et al. (2004) characterized the block of lidocaine and phenol derivatives on human skeletal mus-
cle Na channels using a blocking model (modulated receptor model from Bean et al. 1983), where the 
agents bound and blocked only closed and inactivated channels. They found that about two blocking 
agents would have to bind inactivated Na channels to fit their model to data. However, it is not clear if 
Leuwer et al. (2004) would have obtained the same conclusion had they used a model that permitted the 
anesthetic agents to bind open, closed, and inactivated states.  
Even if LAs can block Na channels at only one site, CAP block reflects the block of many different 
APs exhibiting a range of conduction velocities. AP block is also non-linearly related to Na channel block; 
about 75% of Na channels must be blocked to obtain 50% AP block when membrane APs and block are 
modeled using the Hodgkin-Huxley equations. Agents that alter the Na channel kinetic properties also 
contribute to AP block. In addition, the voltage dependence of Na channel opening is altered in the pres-
ence of local anesthetic agents and this will further complicate the relationship between Na channel block 
and CAP block. 
Kondratiev and Hahin (2001) and Hahin and Kondratiev (2001) showed that straight chain alco-
hols, between two and eight carbons long, block Na channels and CAPs. Logistic fits to dose-response 
curves for all the alcohols blocking Na channels and CAPs were reasonably fit by a single value of   . 
Kondratiev and Hahin (2001) also showed that the alcohols altered the kinetic and voltage-dependent 
properties of Na channels to varying degrees depending on alcohol chain length, causing a reduction in 
Na channel current that indicated channel block.  The effects on kinetic and voltage-dependent properties 
were fairly small or non-existent for the alcohols, suggesting that the alcohols block Na channels in a vir-
tually identical manner.  Therefore, the variability in    observed in the dose-response curves in this work 
suggests that not all the test agents may block Na channels in an identical fashion.    is altered by methyl 
group placement and number on the aromatic ring. 
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The following least-squares regression model predicts    well ( 
       ): 
                                                    
This model suggests that CPs with smaller hydrophobicities, pKa’s, and     s and those with larger mo-
lecular volumes generally have larger    values and, hence, alter Na channels to a greater degree. There 
was no correlation found between      and    when all test agents were regarded as a group. Neverthe-
less, it might be that that the position and arrangement of methyl groups in part   , as Table 3 shows that 
   varies as test agent structure varies. Within each group of CPs, namely the 1NXXCPs, 1NXCPs, 2N-
CPs, and 4mNmTPCP, there was variation in   , which further complicates the determination of the effect 
of chemical structure on   .    decreases as potency increases among the 1NXXCPs ( 
  = 0.977) and 
among the 1NXCPs (   = 0.833), which might suggest that more potent test agents have wider therapeu-
tic ranges. All least-squares regression models were developed in Microsoft Excel 2010 and employed a 
reductive approach, starting with a model including six polynomial powers of each predictor variable and 
then reducing the number of variables one at a time. 
 
1NXXCP Potency  
 
Tonic blocking potency varied as methyl groups were effectively “added” onto the aromatic ring. 
The addition of methyl groups to 1N2CP to either the fifth or sixth positions increased potency; in the lat-
ter case, potency more than doubled. Relative potency was maximized when the aromatic ring methyl 
groups were separated by two positions, i.e., by one unsubstituted aromatic ring carbon; 1N26CP and 
1N35CP have the largest potencies. The methyl group position in 1N3CP was the most effective in caus-
ing CAP block of all 1N-CPs (Table 3), but additions of methyl groups to 1N3CP reduced potency. The 
addition of methyl substituents to 1N3CP to the fourth, fifth, or sixth positions decreased potency, in the 
extreme case by nearly five-fold. Potency again was maximized when the methyl groups were separated 
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by two positions. The shape of the aromatic ring moiety of the test agents, determined by the position and 
arrangements of the methyl groups, plays a role in channel interactions.  
  
Potency and Recovery 
 
     in Table 3 represents the degree of recovery from test agent block at the      concentra-
tion. Recovery represents the degree of CAP height recovery after the test agent is removed from the 
nerve, and test agents with lower recoveries may tend to bind longer to channels and to the nerve and 
may clear the body more slowly. Table 3 suggests that the position of the methyl groups among the 
1NXXCPs and the 2N-CPs determines the degree of recovery.      increases as relative potency de-
creases (    0.909), which suggests that potent channel blockers are associated with small degrees of 
recovery.  
Just as      can be used to determine the relative potency of the test agents,     , or recovery, 
may be used to determine the relative reversibility of binding of the test agents, which in turn might sug-
gest relative toxicity. Bupivacaine and the 2N-CPs had the lowest recoveries, which suggests that the α-
amide linkage leads to smaller recoveries. af Ekenstam et al. (1957) found that the α-amide-based n-alkyl 
pyrrolidine and n-alkyl piperidine carboxylic acid LAs synthesized, when compared with the β-amide and 
the γ-amides, were the most potent and the most toxic, which might suggest that toxicity increases with 
potency. Bupivacaine was shown not only to be associated with a small recovery, but also slow recovery. 
Bupivacine dissociates about ten times slower from cardiac Na channels than lidocaine and does not dis-
sociate quickly enough during diastole to cause complete ventricular AP recovery (Clarkson and Ho-
deghem, 1985). Lidocaine recovery from block is quicker and complete and there is little block accumula-
tion at normal heart rates (Clarkson and Hodeghem, 1985). The rate of dissociation of bupivacaine from 
neuronal Na channels is also ten times or more than lidocaine (Courtney et al. 1978).  
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The results suggest that the 1NXCPs will exhibit the most rapid recovery from channel block and 
likely exhibit the least cardiotoxicity, which makes them appear to have greater promise as useful and 
safe putative LAs. 
 
Phasic Block and Hydrophobicity 
 
All 1N-CPs, except for 1N34CP, showed greater phasic blocking capability as frequency in-
creased. The degree of phasic block increase from 10 pps to 20 pps varied considerably across all test 
agents. The 1N-CPs are virtually permanently uncharged molecules, which, by the trapping hypothesis, 
would suggest that these test should not show use-dependence. However, Table 6 shows that the un-
charged nature of virtually all the CPs is not a determinant of phasic block potency. However, the CPs 
were less effective in causing phasic block than bupivacaine and lidocaine.  
Table 6 further suggests that the position of the methyl groups among the 1N-CPs does not de-
termine phasic blocking capability. The 1NXXCPs exhibited larger degrees of phasic block than the 
1NXCPs. The phasic blocking potencies of the 1NXCPs increased more than those of the 1NXXCPs as 
stimulation rate increased. However, regardless of stimulation rate, the phasic blocking potency increased 
when a methyl group was added to 1N2CP, 1N3CP, or 1N4CP to any position, suggesting increased hy-
drophobicity increases phasic block.  
 
CPs Do Not Preferentially Block Open Channels 
 
Inactivation causes Na channels to become non-conducting shortly after opening due to mem-
brane depolarization. Scorpion α-toxins bind Na channels and cause them to open repeatedly during 
membrane depolarizations by reducing transitions to the inactivated state. BmK 16(5) toxin acted to 
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cause Na channels to open repeatedly to result in long lasting CAPs.  The resulting prolonged CAPs rep-
resent a combination of toxin-modified APs and unmodified APs. The APs arising from the circumferential 
periphery of the nerve were most likely altered by the toxin via diffusion from the solvent and contributed 
to CAP prolongation, while APs from fibers in the interior of the nerve were less or not modified. Thus if a 
test agent preferentially blocks open state channels, then the block of CAP duration should be greater 
than the block of CAP height.  
Bupivacaine and most of the test agents showed no difference in the degree of block of CAP 
heights and CAP durations in α-toxin treated nerves. Lidocaine, 1N34CP, and 1N35CP, the latter two 
having a methyl group at position 3, only blocked CAP durations more than CAP heights. Lidocaine’s 
preferential block of the open state was expected, as it is an anti-arrhythmic agent. Additional CPs, such 
as 1N23CP, 1N33CP, and 1N345CP, should be evaluated to determine if the methyl group at position 3 
is involved in preferential block of the open state. Agents that block the Na channel open state significant-
ly reduce the severity of a number of conditions involving ectopic and/or repetitive AP firing, such as long 
QT syndrome, chronic pain, and convulsions.  
 
Frog, Rat, and Human Na Channels 
 
There were no significant differences in the tonic blocking potencies of bupivacaine, 1N34CP, 
1N3CP, and 4mNmTPCP between frog and rat nerve. These observations suggest that the relative po-
tencies of the test agents obtained from frog experiments will adequately reflect the relative potencies of 
these test agents in rat. Furthermore, relative potency determinations made in rat peripheral nerve will 
likely forecast the relative potencies of CPs for human peripheral nerve since rat Na channels display 
strong sequence similarity to their human counterparts.  
Rat and human alpha subunits of Nav3, present in dorsal root and trigeminal ganglia, show 
strong (89%) primary sequence identity (Lu and Brown, 1998). The SCN3 gene, which codes for Na 
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channels in central and peripheral neurons, is conserved in rats and humans (Lu and Brown, 1998). Also 
there is a considerable degree of sequence identity between Na channels in rat and frog. SCN2A, which 
codes for sodium channel protein type 2 subunit in humans, is conserved in rat and frog: relative to 
SCN2A from Homo sapiens, the Na channel protein type 2 alpha-like subunit from Xenopus tropicalis 
(western clawed frog) is 85.11% identical and SCN2A from Rattus norvegicus is 97.75% identical.  
The open state molecular Na channel model of Lipkind and Fozzard (2005) suggested how amide 
LAs lidocaine, etidocaine, mepivacaine, and bupivacaine dock with the channel to cause block. Lipkind 
and Fozzard (2005) proposed that the tertiary amine portion of LAs interacted with the residues F1579 of 
D4S6 and L1280 of D3S6 from human Nav1.4 and the LA aromatic moieties interacted with residues 
Y1586 of D4S6 and N434 of D1S6. An alignment of Na channel protein type 2 alpha subunits from Homo 
sapiens, Rattus norvegicus, and Xenopus tropicalis is shown below in Figure 33. This alignment shows 
that, relative to the human subunit, the frog and rat subunits have, respectively, 85% and 98% sequence 
identity. The following residues from human (h), rat (r), and frog (f) correspond with the residues Lipkind 
and Fozzard (2005) (LandF) indicate are significant: (LandF)F1579/hF1570/rF1570/fW1570; 
(LandF)L1280/hL1289/ rL1289/fI1289; (LandF)Y1586/hY1588/rW1588/fI1588; and 
(LandF)N434/hN432/rN432/fN432. These similarities between key interaction residues across the species 
and the Lipkind-Fozzard model suggest that LAs will interact similarly with Na channels in all these spe-
cies. Because of the similarities in rat and human Na channel genes, it is likely that relative potencies ob-
tained in this work will be good predictors of relative potencies in human peripheral nerves.  
 
Figure 33. Alignment of Na channel protein type 2 alpha subunits. “*” indicates the amino acid residues 
are identical at that position. : indicates that conserved substitutions have been observed. “.” indicates 
that semi-conserved substitutions have been observed. A blank indicates there is no match among the 










ED50 Estimation  
 
 Among 1N-CPs,      is completely predicted ( 
        ) as a function of pKa, molar volume 
and methyl group positions on the aromatic ring using the following model, obtained using least-squares 
regression analysis. 
where    denotes the position of the first methyl group in the IUPAC name and    denotes the position of 
the second methyl group in the IUPAC name of the test agent. Potency increases if the methyl groups are 
further away from the amide nitrogen (e.g., if they are closer to positions 3 and 4), if pKa increases, and if 
molar volume decreases. However, potency for the 2N-CPs are solely determined by pKa, as equation 
(6) predicts      completely ( 
        ): 
For 2N-CPs, potency increases if pKa decreases. Unlike the 1N-CPs, the placement of the methyl groups 
on the aromatic ring and the molar volume are not significant predictors of the      for 2N-CPs. The 2N-
CPs were shown to be more potent than the 1N-CPs (Table 3). The presence of the α-amide linkage pre-
sent in the 2N-CPs appears significant in increasing the ability of CPs to block CAPs. Consistent with the-
se results, af Ekenstam et al. (1957) found that the α-amide linkage, such as those found in the 2N-CPs, 
conferred greater potency, compared with the β- and γ-amide linkages. Equations (5) and (6) were used 
to estimate the     s for the full range of possible 1NXXCPs, 1NXCPs, 2NXCPs, 2NXXCPs, and 




                                                           
 




                       






Model Estimates of ED50s. 
 
vol = molar volume in mL; pKa = acid dissociation constant;  log P = log octanol-water partition 
coefficient;      = estimated      in mM. Chemical properties were estimated, when not given in 
the literature, using SPARC. 
 
1N-CPs vol pKa log P      2N-CPs vol pKa log P      
1NCP 176.10 0.10 1.91 79.97 2NCP 204.27 8.44 1.37 4.42 
1N2CP 192.30 0.14 2.37 8.73 2N2CP 197.30 8.60 1.83 3.27 
1N3CP 192.30 0.19 2.37 1.70 2N3CP 197.30 8.60 1.83 3.27 
1N4CP 192.30 0.22 2.37 3.58 2N4CP 197.30 8.60 1.83 3.27 
1N22CP 208.73 0.33 2.74 43.49 2N22CP 222.80 8.90 1.59 1.30 
1N23CP 208.73 0.35 2.83 39.67 2N23CP 213.60 8.60 2.29 3.27 
1N24CP 208.73 0.35 2.83 23.76 2N24CP 213.60 8.60 2.29 3.27 
1N25CP 208.73 0.35 2.83 7.85 2N25CP 213.60 8.60 2.29 3.27 
1N26CP 208.73 0.39 2.83 3.94 2N26CP 213.60 8.60 2.29 3.27 
1N33CP 208.73 0.35 2.74 23.16 2N33CP 222.00 8.90 2.54 1.30 
1N34CP 208.73 0.43 2.83 8.63 2N34CP 213.60 8.60 2.29 3.27 
1N35CP 208.73 0.39 2.83 3.34 2N35CP 213.60 8.60 2.29 3.27 
1N44CP 208.73 0.39 2.68 2.74 2N44CP 222.00 8.90 2.54 1.30 
     
2N223CP 238.90 8.90 2.18 1.30 
     
2N224CP 238.90 8.90 2.18 1.30 
     
2N225CP 238.90 8.90 2.18 1.30 
     
2N226CP 238.90 8.90 2.18 1.30 
     
2N233CP 238.90 8.90 3.13 1.30 
     
2N234CP 238.90 8.60 2.75 3.27 
     
2N235CP 238.90 8.60 2.75 3.27 
     
2N236CP 238.90 8.60 2.75 3.27 
     
2N244CP 238.90 8.90 3.13 1.30 
     
2N245CP 238.90 8.60 2.75 3.27 
     
2N246CP 238.90 8.60 2.75 3.27 
     
2N255CP 238.90 8.90 3.20 1.30 
     
2N256CP 238.90 8.60 2.75 3.27 
     






Potential Future Work 
 
 When compared to bupivacaine, novel LA candidates should be similarly potent and long-lasting, 
but less toxic. Since the recovery from block of the 1N-CPs was greater than that of the 2N-CPs, the 1N-
CPs are potentially better novel candidates for LAs. However, since the 2N-CPs lack bupivacaine’s butyl 
group, they may potentially be safer LAs than bupivacaine. The following CPs are recommended for fu-
ture evaluation in rat toxicity and efficacy studies because of their marked potency: 1N3CP, 2N22CP, 
2N33CP, 2N44CP, 2N223CP, 2N224CP, 2N225CP, 2N226CP, 2N233CP, 2N244CP, 2N255CP, and 
2N266CP. 
Experiments designed directly to test the tonic and phasic blocking action of CPs on Na channels 
using the voltage-clamp can be used to verify the findings in this work. The single muscle voltage-clamp 
(Campbell and Hille, 1976; Campbell and Hahin, 1984) can be used to assay CP block of skeletal muscle 
Na channels. Whole cell recording voltage-clamp using the patch-clamp technique (Hamill and Sakmann, 
1981) can be used to study CP block of human heart and other Na channel isoforms. If recombinant heart 
Na channels (Wang et al. 2004) that can’t inactivate are used in whole-cell patch clamp experiments, then 
CPs can be further tested for whether they preferentially block the open state of the Na channel. A num-
ber of the CPs are potential clinical local anesthetics. To obtain preliminary evidence for their potential 
use, experiments must be performed to evaluate their efficacy, safety, and toxicity. 
 Equation (5) gives a wide range of estimated     s for the 1N-CPs, which supports the notion 
that, for the 1N-CPs, the positions of the methyl groups is an essential determinant of     . Equation (6) 
suggests that the potency of the 2N-CPs does not depend on the positions of the methyl groups, but only 
on pKa, which results in much less variability in estimated     . The 1NXXXCPs, 3N-CPs, and 4N-CPs 
were not considered in this work and must be evaluated experimentally to test equations (5) and (6) and 
further expand on the current work. 
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 The CPs act similarly as bupivacaine while being uncharged at physiologic pH, but the CPs have 
pKa values that are significantly less than bupivacaine, other LAs, and other drugs that are injected. Mo-
lecular charge was found not to be a significant factor for producing AP block, but the clinical manifesta-
tions of the significantly low pKa values of the CPs are currently unknown. Nevertheless, a number of 
clinical drugs that are relatively acidic are currently used safely. For example, warfarin, used as an anti-
coagulant, has a pKa of 5.0 and is administered in the form of a sodium salt, as its free acid form is not 
considerably water soluble. Other acidic drugs include the analgesic aspirin (pKa 3.5), antibiotic 
cephalexin (pKa 3.6), the anticonvulsant Clonazepam (pKa 1.4), anti-inflammatory colchicine (pKa 1.7), 
mast cell stabilizer Cromolyn (pKa 2.0), and coumarin derivative proxicromil (pKa 1.9). A significant frac-
tion of acidic drugs are typically uncharged at physiologic pH and must be solubilized in acidic solution, as 
is the case with the CPs.  
 Experiments using select CPs on live rats after in vitro analyses similar to those in this work to 
determine their ability to alleviate pain would be the next step toward developing a novel set of LAs. The 
physiologic effects of the low pKa of the CPs can be investigated by exposure the CPs and other drugs 
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